Analytical Data
-
Gene name
manA
- Application
-
Alternative Names
PhosphohexomutasePhosphomannose isomerase ;PMI
-
Species
Escherichia coli
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P00946
-
Expression Region
1-391aa
-
Molecular Weight
58.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ManA, or mannose-6-phosphate isomerase, is an important enzyme that plays a crucial role in the mannose-6-phosphate (M6P) pathway, which is vital for protein glycosylation and cellular signaling. Research on ManA recombinant proteins has gained significant attention due to their potential applications in biomedical fields, including drug development and gene therapy. The M6P pathway is essential for the proper trafficking of lysosomal enzymes and for the regulation of various cellular processes, including receptor-mediated endocytosis. Abnormalities in this pathway are linked to several diseases, including lysosomal storage disorders and cancer, making ManA an attractive target for therapeutic interventions. The study of ManA recombinant proteins involves their expression, purification, and characterization, aiming to understand their structure-function relationship and develop potential enzyme replacement therapies. Advances in molecular cloning and expression technologies have enabled researchers to produce high-yield recombinant ManA proteins, facilitating detailed biochemical studies and the exploration of their pharmacological potential. Understanding the functional dynamics of ManA not only enhances our knowledge of cellular metabolism but also opens pathways for innovative therapeutic strategies in managing diseases associated with glycosylation defects. This is particularly important for developing novel treatments that leverage the enzyme's specificity and mechanism, potentially leading to improved outcomes for patients with related metabolic disorders. Overall, ongoing research into ManA recombinant proteins holds promise for fostering advancements in therapeutic applications and understanding fundamental biological processes.
